GIM
REGN icon

Granahan Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Granahan Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-124,800
Closed -$39M – 218
2013
Q3 		$39M Sell
124,800
-13,100
-9% -$3.45M 1.04% 21
2013
Q2 		$31M Buy
+137,900
New +$32.1M 0.89% 34

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Granahan Investment Management's REGN Position: Q4 2013 in Review

Granahan Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2013, closing a stake of 124,800 shares — an estimated $39M sold.

Granahan Investment Management first reported a position in REGN in Q2 2013 and held it in 2 quarters. The position peaked at $39M in Q3 2013. 438 funds tracked by Wall St. Rank hold REGN as of Q4 2013.

  • Granahan Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Granahan Investment Management sold 124,800 Regeneron Pharmaceuticals shares in Q4 2013, an estimated $39M.
  • Granahan Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Granahan Investment Management's Regeneron Pharmaceuticals position peaked at $39M in Q3 2013.
  • 438 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2013.

Based on Granahan Investment Management's 13F filing for Q4 2013, filed 30 Jan 2014.